Fax: (773) 702-9903
Estrogen receptor-β expression in extraabdominal fibromatoses
An analysis of 40 cases
Article first published online: 6 DEC 2005
Copyright © 2005 American Cancer Society
Volume 106, Issue 1, pages 208–213, 1 January 2006
How to Cite
Deyrup, A. T., Tretiakova, M. and Montag, A. G. (2006), Estrogen receptor-β expression in extraabdominal fibromatoses. Cancer, 106: 208–213. doi: 10.1002/cncr.21553
- Issue published online: 23 DEC 2005
- Article first published online: 6 DEC 2005
- Manuscript Accepted: 19 JUL 2005
- Manuscript Revised: 23 JUN 2005
- Manuscript Received: 4 APR 2005
- estrogen receptor (ER);
- estrogen receptor-β;
Early experiments using ligand-binding assays demonstrated the presence of estrogen receptor (ER) in fibromatoses. These findings were not confirmed by later studies using immunohistochemical analysis.
To verify the expression of ERs in fibromatosis as well as to clarify the inconsistency between radioligand and early immunohistochemical studies, the authors examined a series of 40 extraabdominal fibromatoses using antibodies raised against ERβ.
All 40 cases of extraabdominal fibromatosis were at least focally positive for ERβ. Thirty-three of 40 (83%) displayed 3+ (>50%) expression, 5 of 40 (12%) were 2+ (11–50%), and 2 of 40 (5%) cases showed 1+ (<10%) expression. All cases were negative for ERα.
Although extraabdominal fibromatosis does not express ERα, there appears to be nearly uniform expression of ERβ. This finding clarifies discrepancies in the literature regarding estrogen expression in fibromatosis, and provides a biological mechanism for the action of antiestrogenic compounds in the treatment of fibromatosis. Estrogen antagonists may have a role in the treatment of refractory or recurrent extraabdominal fibromatoses. Cancer 2006. © 2005 American Cancer Society.